Literature DB >> 3775862

Aerogenic vaccination of mice with Mycobacterium bovis BCG.

I M Orme, F M Collins.   

Abstract

The course of infection with Mycobacterium bovis BCG Pasteur was followed against time in groups of mice vaccinated by either the aerogenic or subcutaneous route. The generation of acquired protective immunity and immunological memory was determined in each group by adoptive immunisation procedures. In addition, subcutaneously vaccinated mice were tested for their ability to resist an aerogenic challenge with a lethal dose of M. tuberculosis. No overall qualitative differences in the magnitude or longevity of antituberculosis immunity in mice vaccinated by the two procedures were observed. It is concluded that aerogenic vaccination offers no immunological advantage over vaccination by the subcutaneous route.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3775862     DOI: 10.1016/0041-3879(86)90007-3

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


  16 in total

1.  Anamnestic responses of mice following Mycobacterium tuberculosis infection.

Authors:  Arati B Kamath; Samuel M Behar
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Intranasal administration of Mycobacterium bovis BCG induces superior protection against aerosol infection with Mycobacterium tuberculosis in mice.

Authors:  Steven C Derrick; Kristopher Kolibab; Amy Yang; Sheldon L Morris
Journal:  Clin Vaccine Immunol       Date:  2014-08-20

3.  Protective immunity to experimental tuberculosis by mannophosphoinositides of mycobacteria.

Authors:  P K Mehta; G K Khuller
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

4.  Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium bovis BCG immunization.

Authors:  Umaimainthan Palendira; Andrew G D Bean; Carl G Feng; Warwick J Britton
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

5.  Naturally attenuated, orally administered Mycobacterium microti as a tuberculosis vaccine is better than subcutaneous Mycobacterium bovis BCG.

Authors:  Yukari C Manabe; Cherise P Scott; William R Bishai
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

6.  Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis.

Authors:  Lihao Chen; Jun Wang; Anna Zganiacz; Zhou Xing
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Effective, nonsensitizing vaccination with culture filtrate proteins against virulent Mycobacterium bovis infections in mice.

Authors:  C M Bosio; I M Orme
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

Review 8.  Early T-cell responses in tuberculosis immunity.

Authors:  Gary M Winslow; Andrea Cooper; William Reiley; Madhumouli Chatterjee; David L Woodland
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

9.  Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG.

Authors:  E L Nuermberger; T Yoshimatsu; S Tyagi; W R Bishai; J H Grosset
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

10.  Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis.

Authors:  Marcela I Henao-Tamayo; Diane J Ordway; Scott M Irwin; Shaobin Shang; Crystal Shanley; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2010-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.